Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Cancer Treatment and Research
|
February 20, 2007
NCI's cancer therapy evaluation program: a commitment to treatment trials
Jeffrey S Abrams, Anthony Murgo, Michaele C Christian
The Oncologist
|
July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors
Gideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
The Oncologist
|
May 29, 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
Sean Khozin, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia
Louise H Cragg, Michael Andreeff, Eric Feldman, et al.
Gynecologic Oncology
|
October 4, 2005
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium
D Yi-Shin Kuo, Patrick Timmins, Stephanie V Blank, et al.
Cancer
|
December 13, 2006
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
Alfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study
Sébastien J Hotte, Eric W Winquist, Elizabeth Lamont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2003
Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study
Naomi B Haas, Mitchell Smith, Nancy Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2005
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group
Stacey L Berg, Susan M Blaney, Meenakshi Devidas, et al.
Cancer
|
April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia
Susan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Cancer Treatment and Research
|
February 20, 2007
NCI's cancer therapy evaluation program: a commitment to treatment trials
Jeffrey S Abrams, Anthony Murgo, Michaele C Christian
The Oncologist
|
July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors
Gideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
The Oncologist
|
May 29, 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
Sean Khozin, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia
Louise H Cragg, Michael Andreeff, Eric Feldman, et al.
Gynecologic Oncology
|
October 4, 2005
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium
D Yi-Shin Kuo, Patrick Timmins, Stephanie V Blank, et al.
Cancer
|
December 13, 2006
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
Alfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study
Sébastien J Hotte, Eric W Winquist, Elizabeth Lamont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2003
Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study
Naomi B Haas, Mitchell Smith, Nancy Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2005
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group
Stacey L Berg, Susan M Blaney, Meenakshi Devidas, et al.
Cancer
|
April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia
Susan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Page
of 2